GSK and Moderna Reach Global Settlement to End Intellectual Property Disputes Over COVID-19 and RSV Vaccines

British pharmaceutical giant GSK and biotechnology innovator Moderna have officially resolved their high-stakes intellectual property dispute. The companies announced that they have settled lingering lawsuits which accused Moderna’s prominent COVID-19 vaccines, Spikevax and mNEXSPIKE, alongside its respiratory syncytial virus (RSV) shot mResvia, of infringing upon foundational GSK patents.

The agreement, which brings an end to protracted legal friction across multiple jurisdictions, establishes a clean slate for both multinational corporations without the burden of ongoing litigation costs or financial penalties. According to a formal press release issued by Moderna, the two companies resolved GSK’s sweeping patent litigation spanning both the United States and Europe. The formal settlement was reached on October 28, following joint legal filings submitted earlier in the month.

Under the terms of the newly minted agreement, Moderna and GSK have granted mutual patent cross-licenses within the specialized field of infectious disease. Crucially, the companies confirmed that neither party is obligated to make financial payments of any kind in connection with these cross-licenses, removing what could have been a significant barrier to commercialization and collaborative research in the vaccine sector.

A spokesperson for GSK echoed the sentiment of cooperative resolution, stating that the British drugmaker was pleased to have reached an agreement that delivers much-needed clarity for both organizations. The representative added that the settlement enables both companies to maintain an uninterrupted focus on advancing vital scientific innovation for patients worldwide.

The legal wind-down materialized in a Delaware federal court, where attorneys representing both pharmaceutical companies asked the presiding judge on October 6 to officially dismiss GSK’s U.S. patent infringement claims. The dismissal was requested with prejudice, meaning that the specific infringement claims brought forward in this action cannot be refiled in the future, effectively closing this chapter of litigation between the two developers.

The underlying conflict dates back to 2024, when GSK initiated legal action against Moderna. At the heart of the dispute was sophisticated lipid nanoparticle technology, a crucial delivery system utilized in modern vaccines to safely transport fragile messenger RNA into the human body without degrading before it can trigger an immune response. This lipid nanoparticle delivery mechanism is widely considered a cornerstone of modern mRNA vaccine development, making intellectual property surrounding its design and application immensely valuable.

The lawsuit against Moderna was not an isolated move by the British drugmaker. Earlier that same year, GSK filed a separate, highly similar patent infringement lawsuit against pharmaceutical titan Pfizer and its German partner BioNTech, targeting the lipid nanoparticle technology implemented in their widely distributed COVID-19 vaccine. Unlike the agreement reached with Moderna, GSK’s legal battle against Pfizer and BioNTech remains active and ongoing in the courts.

This resolution arrives against the backdrop of a broader, highly complex web of ongoing U.S. court cases involving major vaccine manufacturers. Pfizer, BioNTech, and Moderna have frequently found themselves entangled in multifaceted legal challenges over patent royalties and the proprietary technologies that underpinned the global rollout of COVID-19 vaccines during and after the pandemic. Among these numerous intellectual property skirmishes is a separate lawsuit brought by Moderna against Pfizer back in 2022, highlighting an industry-wide scramble to establish legal boundaries and commercial rights over breakthrough vaccine science that changed the landscape of global public health.